|
C1ORF210 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.10469999709184E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.80990000051307E-08 |
| Normal-vs-Stage2 |
2.683900E-02 |
| Normal-vs-Stage3 |
3.93240000007289E-07 |
| Normal-vs-Stage4 |
4.32650004711377E-09 |
| Stage1-vs-Stage2 |
1.566350E-01 |
| Stage1-vs-Stage3 |
6.245200E-01 |
| Stage1-vs-Stage4 |
9.384300E-02 |
| Stage2-vs-Stage3 |
1.151410E-01 |
| Stage2-vs-Stage4 |
1.841590E-02 |
| Stage3-vs-Stage4 |
2.510000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.09139999657526E-09 |
| Normal-vs-AfricanAmerican |
2.735800E-03 |
| Normal-vs-Asian |
1.85079995773663E-09 |
| Caucasian-vs-AfricanAmerican |
5.585800E-01 |
| Caucasian-vs-Asian |
7.619700E-02 |
| AfricanAmerican-vs-Asian |
9.154000E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.4038000000216E-06 |
| Normal-vs-Female |
3.80810000200071E-08 |
| Male-vs-Female |
9.172800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.74770000086022E-08 |
| Normal-vs-Age(41-60Yrs) |
1.85230000004921E-06 |
| Normal-vs-Age(61-80Yrs) |
1.55998999999962E-05 |
| Normal-vs-Age(81-100Yrs) |
1.439590E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.997000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.133400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.819400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.313400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.421600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.721800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.245100E-04 |
| Classical-VS-Follicular |
7.094300E-02 |
| Classical-VS-Other |
9.235000E-01 |
| Classical-VS-Normal |
3.07040000091519E-08 |
| Tall-VS-Follicular |
3.70950000000425E-05 |
| Tall-VS-Other |
3.145000E-01 |
| Tall-VS-Normal |
3.44246853245522E-12 |
| Follicular-VS-Other |
6.261600E-01 |
| Follicular-VS-Normal |
1.482500E-03 |
| Other-VS-Normal |
3.259800E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.88119999999992E-05 |
| Normal-vs-N1 |
1.22650001266322E-10 |
| N0-vs-N1 |
1.322550E-03 |
|
|
